Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 1
2002 2
2004 3
2005 3
2006 2
2007 7
2008 7
2009 4
2010 10
2011 18
2012 11
2013 18
2014 12
2015 15
2016 16
2017 14
2018 15
2019 9
2020 7
2021 6
2022 6
2023 8
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Results by year

Filters applied: . Clear all
Page 1
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM. Cortes JE, et al. Among authors: nicolini fe. Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22. Blood. 2018. PMID: 29567798 Free PMC article. Clinical Trial.
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Müller MC, Ernst T, Rosti G, Porkka K, Baccarani M, Cross NC, Martinelli G. Soverini S, et al. Among authors: nicolini fe. Blood. 2011 Aug 4;118(5):1208-15. doi: 10.1182/blood-2010-12-326405. Epub 2011 May 11. Blood. 2011. PMID: 21562040 Free article. Review.
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Kantarjian HM, Jabbour E, Deininger M, Abruzzese E, Apperley J, Cortes J, Chuah C, DeAngelo DJ, DiPersio J, Hochhaus A, Lipton J, Nicolini FE, Pinilla-Ibarz J, Rea D, Rosti G, Rousselot P, Shah NP, Talpaz M, Srivastava S, Ren X, Mauro M. Kantarjian HM, et al. Among authors: nicolini fe. Am J Hematol. 2022 Nov;97(11):1419-1426. doi: 10.1002/ajh.26686. Epub 2022 Aug 30. Am J Hematol. 2022. PMID: 36054756 Free PMC article.
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. Cortes JE, et al. Among authors: nicolini fe. N Engl J Med. 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494. Epub 2013 Nov 1. N Engl J Med. 2013. PMID: 24180494 Free PMC article. Clinical Trial.
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators. Saussele S, et al. Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4. Lancet Oncol. 2018. PMID: 29735299 Clinical Trial.
Pr Connie J. Eaves (1944–2024).
Audet J, Berger M, Cashman J, Chalandon Y, Coulombel L, Flamant S, Ghaffari S, Lefort S, Lemoine F, Maguer-Satta V, Nicolini FE, Schmitt C, Sloma I, Turhan A. Audet J, et al. Among authors: nicolini fe. Bull Cancer. 2024 May 16:S0007-4551(24)00160-7. doi: 10.1016/j.bulcan.2024.05.001. Online ahead of print. Bull Cancer. 2024. PMID: 38760290 French. No abstract available.
Dasatinib-induced acute hepatitis.
Bonvin A, Mesnil A, Nicolini FE, Cotte L, Michallet M, Descotes J, Vial T. Bonvin A, et al. Among authors: nicolini fe. Leuk Lymphoma. 2008 Aug;49(8):1630-2. doi: 10.1080/10428190802136384. Leuk Lymphoma. 2008. PMID: 18608866 No abstract available.
T315I+ tyrosine-kinase independent CML cells resistance.
Nicolini FE, Grockowiak E, Maguer-Satta V. Nicolini FE, et al. Oncotarget. 2017 Jul 4;8(27):43600-43601. doi: 10.18632/oncotarget.18573. Oncotarget. 2017. PMID: 28642447 Free PMC article. No abstract available.
172 results